What You Should Know:
– Asepha, a fast-growing startup leveraging AI agents for pharmacy automation, today announced the close of its $4 million Seed round, led by Glasswing Ventures and Core Innovation Capital.
– Panache, RedBud, and MGV also participated, with follow-on support from Ripple Ventures and Front Row Ventures.
Asepha Raises the Bar on AI-Driven Pharmacy Automation, Expands Nationwide Footprint
Asepha is redefining pharmacy operations with cutting-edge, AI-powered tools that automate core administrative tasks—drastically improving efficiency and access to care. Founded in 2023 by pharmacist Dr. Eunice Wu and AI engineer Can Uncu—both first-generation immigrants with deep domain expertise—Asepha is tackling one of healthcare’s most pressing challenges: understaffed pharmacies overwhelmed by analog workflows.
With over 70% of pharmacies currently operating below ideal staffing levels and pharmacists spending up to 90% of their time on manual work, Asepha is offering timely, targeted relief. Its modular suite of interoperable agents is engineered to reduce administrative burden while accelerating speed and accuracy. These include:
- A high-accuracy OCR prescription entry agent that processes complex handwritten prescriptions with 96% precision
- An AI call agent capable of automating up to 70% of inbound phone triage, significantly reducing call volume for staff
- A browser navigation agent that completes repetitive web-based tasks in real time, streamlining administrative workflows
In validation trials, Asepha’s AI-generated responses were favored over those of human pharmacists 71% of the time in a double-blinded randomized evaluation—demonstrating not just efficiency, but user trust and reliability.
Backed by new funding, Asepha plans to scale its engineering and commercial teams, expand U.S. operations with a newly established New York City office, and deepen its global partnerships. The company has already onboarded multiple Fortune 50 enterprise clients, underscoring its early momentum and market relevance.
“As a pharmacist, I saw firsthand how manual workflows distract from patient care,” said Dr. Wu. “With Asepha, we’re returning time and focus to what truly matters—patients. This next stage of growth will bring real relief to care teams and improve access for tens of millions of people.”
Co-founder Can Uncu brings critical AI hardware experience from his time at AMD, where he worked on the MI300X chip—now powering OpenAI and Microsoft Azure. Together, Wu and Uncu are positioning Asepha at the forefront of AI transformation in pharmacy, ensuring tools are built not just for efficiency, but for impact.
